Clinical trialsCompany release
Lexeo reports interim LX2020 data in PKP2 cardiomyopathy, cites FDA openness to NSVT endpoint
🇺🇸 Lexeo Therapeutics, Inc. (LXEO) · Mon 16 Nov 2026
Interim results for the gene therapy show falls in arrhythmia measures, and the company says FDA is open to a surrogate endpoint for accelerated approval.
Lexeo Therapeutics has reported interim data for its gene therapy LX2020 in arrhythmogenic cardiomyopathy linked to PKP2 mutations. The figures come from the company's investor presentation, dated 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Lexeo Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Lexeo Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ
🇺🇸 Cerenome, Inc. (CNSY) · Mon 16 Nov 2026
Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial
Clearmind Medicine Inc. (CMND) · Mon 16 Nov 2026
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 16 Nov 2026
CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer
🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026
Aptevo's mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall
🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 16 Nov 2026
Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF
🇺🇸 Rein Therapeutics, Inc. (RNTX) · Mon 16 Nov 2026